drug
eteplirsen
Marketedupdated 6mo agoby $SRPT Sarepta Therapeutics, Inc.
Approvedcommunity read0 votes
indications
investigational
Duchenne Muscular Dystrophy
all catalysts(0)
nothing on the calendar yet
Trials studying eteplirsen
- phase3A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
- —A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
- phase2Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
- phase2A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.
- phase2A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 27, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Mar 14, 2034method-of-use (U-1918)US 10337003
- Mar 14, 2034method-of-use (U-1918)US 10337003
- Mar 14, 2034method-of-use (U-1918)US 10364431
- Mar 14, 2034method-of-use (U-1918)US 10364431
- Mar 14, 2034method-of-use (U-1919)US 9506058
- Mar 14, 2034method-of-use (U-1919)US 9506058
- Feb 2, 2029formulationUS RE477692.2y
- Feb 2, 2029formulationUS RE477692.2y
- Oct 27, 2028method-of-use (U-2097)US RE484681.9y
- Oct 27, 2028method-of-use (U-2097)US RE484681.9y
News(3)
- Sarepta’s new CEO confident in clinical execution as DMD competitors close inSarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.biospace · 11d ago
- On the move: 4 rare disease companies hiring nowBiotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.biospace · 1mo ago
- Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ reviewIf approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…biospace · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that